Skip to main content

ARGX · Argenx SE

Track ARGX — free
$950.79 -0.16 (-0.02%)
Market Cap
$59.80B
Shares
62.89M
Volume · Nov 17 259.14K Avg daily vol (3M) 366.31K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$950.95 Open$970.48 Day$948.21–981.42 52W close$663.93–1,058.90 Avg vol 30d470K Short int1.4M · 2.2% of shares · 3.4d Short vol45% Last earningsOct 22, 2026 DataJan 2020–Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 10
Investor event
Five launches target broader growth pipeline

Argenix expects five potential launches, with IM&M the largest growth contributor, and plans continued disciplined business development. It also announced the UNP acquisition, subject to customary closing conditions, while expecting revenue growth to exceed OPEX growth.

6 source passages
Yeah, potentially five launches. I think probably the biggest growth percentage, growth number, will come from IM&M, immune-mediated necrotizing myositis. because Argenix is known for VivGuard. I think you can expect us to continue doing business development also in the future as we build the company for the long run and as we deliver on Vision 2030. yesterday we announced the acquisition of UNP, natural products. Of course, it's still subject to all the customary closing conditions. revenue growth currently is at a higher percentage than OPEX growth Open the document at this passage
Nov 9
Current report 6-K
Phase 3 trial supports planned IMNM regulatory submission

argenx said the Phase 3 ALKIVIA study of efgartigimod met primary and key secondary endpoints in combined IMNM and DM populations; it plans to submit an sBLA for IMNM by the end of 2026.

3 source passages
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 The study met its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patient population, demonstrating that patients treated with efgartigimod achieved a statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (p=0.0011; 48.0 vs 32.6). Based on the ALKIVIA results, argenx plans to submit a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for efgartigimod in IMNM by the end of 2026, supported by a Breakthrough Therapy Designation from the FDA. Open the document at this passage
Nov 9
Current report 6-K
Acquisition of Unnatural Products valued at up to $1.15 billion

argenx will acquire all remaining shares of Unnatural Products, Inc. (UNP), with $550 million upfront and up to $595 million in development and regulatory milestone payments; closing is expected by the end of the year.

3 source passages
argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. Under the terms of the agreement, argenx will acquire UNP for an upfront payment of $550 million in cash on hand and up to $595 million in payments contingent on achievement of specified development and regulatory milestones, for total potential consideration of up to approximately $1.15 billion. The acquisition is expected to close by the end of the year, subject to customary closing conditions. Open the document at this passage
Oct 22
Earnings call
Q3 2026 earnings call

Argenix reported product net sales of $1.7 billion, up 54% year-over-year, and expects up to five U.S. launches in 2027. It plans an IM&M filing by year-end and an MMN Phase III readout in December.

Oct 22
Current report 6-K
Current report

argenx SE generated third-quarter VYVGART net sales of $1.7 billion, up 54% year-over-year, and profit of $0.5 billion. VYVGART Hytrulo’s IMNM sBLA is on track for submission by year-end 2026; empasiprubart Phase 3 MMN data are expected in December 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.33B
Trailing 12 months
Net income (TTM)
$1.72B
Trailing 12 months
Revenue growth YoY
+88.6%
Year over year
Operating margin
30.1%
Trailing 12 months
P / E (TTM)
35.2
Trailing earnings · reciprocal yield 2.8%
FCF yield
1.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.8%
Year over year · more shares
Price change (1Y)
+7.7%
Trailing year
Short interest
2.2%
Latest settlement · 3.4 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 22.9 · elevated Equity put/call 0.73
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +10%
above
Price vs 50-day avg +3%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 73%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +15%
trailing
6-month return +16%
trailing
YTD return +13%
this year
Relative strength +17%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $922 › 200d $861 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +90 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.25% of shares out · ▲ +4.3% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
550 holders — near 3-yr high, broad support
Squeeze score 63
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 38%
annualized · 1-yr
Max drawdown −29%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+10% Bullish
Price vs 50-day avg
+3% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
73% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $922 › 200d $861 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +90 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.25% of shares out · ▲ +4.3% MoM · 3.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
550 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $664 Now $951 · 73% Range high $1,059
vs 200-day avg +10% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ARGX
Argenx SE
this stock
$59.80B +13.1% — — 2.2%
VRTX
Vertex Pharmaceuticals Inc
$136.35B +18.6% +46.2% 34.6 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.52B +23.4% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$83.08B +630.0% +4.3% — 8.2%
CSLLY
Csl Ltd
$65.26B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
550
% held
44.2%
Net QoQ
-435.3K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
373
View
Short & Settlement
Short Interest Rising
Shares short
1.4M
Days to cover
3.4d
Change
+58.8K sh
View
Short Volume
Short vol %
45%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
2.8K
Value
$2.5M
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
43.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Oct 27, 2026
View
Financials
Financials
Net income (FY)
EUR -163.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
40

Argenix expects five potential launches, with IM&M the largest growth contributor, and plans continued disciplined business development. It also announced the UNP acquisition, subject to customary closing conditions, while expecting revenue growth to exceed OPEX growth.

View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
argenx to Acquire Unnatural Produ…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
ARGX -1.2% +15.2% +15.9% +6.5% +13.1%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY +0.5% +18.6% +17.3% +8.6% +4.6%
Key facts CIK 1697862 CUSIP 04016X101 13F (30d) 559 filings 506 filers Visit website Investor relations